title: A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.
abstract: OBJECTIVE
  AUY922 is a novel heat shock protein inhibitor with preclinical activity in pancreatic cancer. This phase II study evaluated the efficacy of AUY922 in patients with advanced pancreatic cancer previously treated with chemotherapy.
  
  
  METHODS
  In this single-arm, Simon two-stage phase II trial, patients with metastatic or locally advanced pancreatic ductal adenocarcinoma who had progressed on at least one line of chemotherapy and were of good performances status (ECOG 0 or 1) were treated with AUY922 at a dose of 70 mg/m(2) IV weekly. The primary endpoint was disease control rate (objective response and stable disease ≥16 weeks).
  
  
  RESULTS
  Twelve patients were accrued, all of whom received treatment. At least possibly related ≥grade 3 adverse events included fatigue (8 %) and AST elevation (8 %). Ten patients were evaluable for response with 1 (10 %) having stable disease and 9 (90 %) progressive disease. The median progression-free survival was 1.6 months, and the median overall survival was 2.9 months.
  
  
  CONCLUSIONS
  AUY922 was not associated with significant efficacy in previously treated patients with advanced pancreatic cancer.
authors.affiliation: British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, BC, V5Z4E6, Canada. drenouf@bccancer.bc.ca.
authors.forename: D J
authors.initials: DJ
authors.lastname: Renouf
authors.affiliation: University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Hedley
authors.affiliation: University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: M K
authors.initials: MK
authors.lastname: Krzyzanowska
authors.affiliation: University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Schmuck
authors.affiliation: University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.affiliation: British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, BC, V5Z4E6, Canada.
authors.forename: M J
authors.initials: MJ
authors.lastname: Moore
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012118:Resorcinols / Q000008:administration & dosage* / Q000009:adverse effects; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: C528044:5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D007555:Isoxazoles; D012118:Resorcinols
keywords: AUY922; Pancreatic cancer; Phase II